Table 2 Time to disease progression and PFS by drug category and treatment line – from chart review
Variable | First-line treatment | n | # Censored obs.a | Median (months) | 95% confidence interval | p-valueb | |
|---|---|---|---|---|---|---|---|
Lower limit | Upper limit | ||||||
Time to disease progression on first-line therapy (months) from start of first-line therapy | Aromatase inhibitors | 103 | 8 | 12.0 | 10.0 | 13.1 | |
Chemotherapy | 25 | 13 | 7.9 | 6.0 | 8.3 | ||
Other | 50 | 8 | 11.9 | 7.0 | 17.3 | 0.3563 | |
Progression- free survival on second line therapy (months) from start of second-line therapy | Aromatase inhibitors | 103 | 16 | 7.4 | 5.7 | 8.4 | |
Chemotherapy | 25 | 8 | 7.3 | 5.1 | 11.2 | ||
Other | 50 | 19 | 8.1 | 7.0 | 12.0 | 0.1047 | |
Progression- free survival on third-line therapy (months) from start of third-line therapy | Aromatase inhibitors | 55 | 23 | 8.0 | 3.4 | 12.0 | |
Chemotherapy | 11 | 6 | 9.0 | 1.4 | NE | ||
Other | 20 | 7 | 5.2 | 4.0 | 14.1 | 0.9176 | |